Takeda Pharmaceuticals and Lundbeck have jointly announced the submission of a New Drug Application (NDA) to the US FDA for the investigational agent vortioxetine. Vortioxetine (Lu AA21004 ...

Vortioxetine is an antidepressant used for the treatment of major depressive disorder (MDD) in adults and also investigated as a treatment for generalized anxiety disorder (GAD).

This meta-analysis demonstrated the efficacy of vortioxetine in reducing depression symptoms in adult patients with MDD. Based on both depression rating scales (MADRS and HAM-D24) a significant ...

Researchers also conducted tests with vortioxetine on mice with glioblastoma. Related News | Scientists say the drug showed ...

As shown in Figure 4, the odds of vortioxetine treated patients achieving a ≥50% MADRS score reduction from baseline was about 3 times higher than placebo treated patients (Overall OR = 2.87 ...